SGN-70

Description

SGN-70 is a humanized monoclonal antibody that targets the CD70 antigen. CD70 is expressed on activated T- and B-cells but not resting lymphocytes, and has been associated with a variety of autoimmune and inflammatory disorders. SGN-70 has been shown in preclinical models to selectively deplete CD70-positive lymphocytes and block the co-stimulation pathway between CD70 and its receptor, CD27.

Development Status

Seattle Genetics is developing SGN-70 as a novel therapy for autoimmune disease. By specifically targeting activated T- and B-cells, SGN-70  may reduce the damaging effects of autoimmune disease without globally suppressing the immune system. SGN-70 is in a phase I clinical trial designed to assess its safety, tolerability and pharmacokinetics in healthy volunteers.